Lexicon Pharmaceuticals (NASDAQ:LXRX) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Key Points

• Lexicon Pharmaceuticals' stock price surpassed its 200-day moving average of $0.78, reaching a high of $1.14, with current trading at $1.10.
• Analysts have rated the stock as a "Moderate Buy," with a consensus target price of $3.23, with Citigroup raising its price target from $1.20 to $1.90.
• The company reported an EPS of $0.01 for its recent quarter, significantly exceeding the expected loss of ($0.08), along with revenue of $28.87 million versus an estimate of $4.87 million.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report)'s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.78 and traded as high as $1.14. Lexicon Pharmaceuticals shares last traded at $1.10, with a volume of 1,453,797 shares traded.

Analyst Ratings Changes

A number of research analysts have commented on LXRX shares. HC Wainwright restated a "buy" rating and set a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, September 2nd. Citigroup upped their price objective on Lexicon Pharmaceuticals from $1.20 to $1.90 and gave the stock a "buy" rating in a research report on Thursday, August 7th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $3.23.

Lexicon Pharmaceuticals Stock Down 2.5%

The company has a debt-to-equity ratio of 0.43, a current ratio of 4.16 and a quick ratio of 4.16. The company has a market cap of $432.45 million, a price-to-earnings ratio of -3.61 and a beta of 1.26. The firm's 50 day simple moving average is $1.14 and its 200-day simple moving average is $0.80.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The firm had revenue of $28.87 million for the quarter, compared to analyst estimates of $4.87 million. Lexicon Pharmaceuticals had a negative return on equity of 83.63% and a negative net margin of 206.43%. As a group, sell-side analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $541,000. Monaco Asset Management SAM purchased a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $338,000. Acadian Asset Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the 1st quarter worth approximately $263,000. Deutsche Bank AG increased its stake in shares of Lexicon Pharmaceuticals by 378.0% during the 4th quarter. Deutsche Bank AG now owns 315,659 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 249,616 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Lexicon Pharmaceuticals by 193.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 353,508 shares of the biopharmaceutical company's stock worth $261,000 after purchasing an additional 233,121 shares in the last quarter. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.